Latest nasal allergy Stories
Higher-than-Normal Pollen Counts Increase Demand for Superior Performing Nasal Breathing Relief BEVERLY, Mass., May 14, 2014 /PRNewswire/ --
Nasal allergy sufferers now have the most effective player on their team to relieve even the toughest nasal allergy symptoms CHATTANOOGA, Tenn., April 15, 2014 /PRNewswire/ -- Nancy
SAN FRANCISCO, March 21, 2011 /PRNewswire/ -- Results from a recent pivotal allergic rhinitis (AR) satisfaction survey assessing patient and healthcare provider perspectives on AR reveal that symptoms like nasal congestion and post-nasal drip continue to impact patients' daily activities.
BRIDGEWATER, N.J., March 10 /PRNewswire/ -- Sanofi-aventis U.S. today announced the launch of the Clean Sweep campaign to help guide spring cleaning for the estimated 60 million Americans who are affected by nasal allergies.
Exposing patients with chronic sinus disease to allergens and then obtaining repeated images by X-ray or ultrasound reveals that nasal allergies may be involved in some cases of chronic sinus disease.
ATLANTA and BRIDGEWATER, N.J. Sept. 8 /PRNewswire/ -- From cubbies and carpets to class pets and pollen, as parents prepare for this year's back to school they should also prepare for the upcoming fall allergy season.
Simple Steps Can Make a Big Difference in Managing Indoor and Outdoor Allergies ATLANTA and BRIDGEWATER, N.J., March 2 /PRNewswire-FirstCall/ -- As this year's spring nasal allergy season quickly approaches, people living with nasal allergies should take steps to manage their symptoms and ward-off allergens before they hit home.
KENILWORTH, N.J., July 17 /PRNewswire-FirstCall/ -- Schering-Plough Corporation today announced that Schering-Plough K.K., the company's country operation in Japan, has received marketing approval for NASONEX(R) (mometasone furoate monohydrate) Nasal Spray 50mcg* for the treatment of allergic rhinitis in adult patients.(1) NASONEX is an intranasal steroid that significantly improves nasal allergy symptoms when taken once each day.
Sepracor Inc. (Nasdaq: SEPR) announced today the launch of "My Allergies in America" (www.myallergiesinamerica.com), a comprehensive resource for physicians and consumers based on the two-part, landmark "Allergies in America" survey of adults, adolescents and children with allergic rhinitis.